• info@imunodiagnostika.lt
  • +370 5 2469088

Blog

Rekombinantinių alergenų producentų kūrimas

UAB „Imunodiagnostika“ įgyvendino projektą „Rekombinantinių alergenų producentų kūrimas“, Nr. 01.2.1-MITA-T-851-02-0218 finansuojamą iš Europos regioninės plėtros fondo. (projekto biudžetas – 46 826 EUR).

Projekto tikslas – genų inžinerijos metodais sukurti rekombinantinių baltymų raiškos technologijas, skirtas alergijų diagnostikai svarbių įrankių kūrimui.

Rekombinantinių alergenų producentai, sintetinantys biotechnologiniius produktus, kurie bus kuriami šiame projekte, turės didelę diagnostinę vertę, t. y. pagerins diagnostinių testų jautrumą ir specifiškumą.

Projekto veiklų įgyvendinimo pradžia – 2020-11-03

Projekto veiklų įgyvendinimo pabaiga – 2021-10-31

UAB „Imunodiagnostika“ investicijos į su COVID-19 susijusias MTEP veiklas

UAB „Imunodiagnostika“ įgyvendina projektą „UAB „Imunodiagnostika“ investicijos į su COVID-19 susijusias MTEP veiklas“, Nr. 01.2.1-LVPA-T-858-01-0003 finansuojamą iš Europos regioninės plėtros fondo. Finansuojama kaip Europos Sąjungos atsako į COVID-19 pandemiją priemonė (projekto biudžetas – 582.094,59 EUR, skirtas finansavimas – 465.675,67 EUR).

The aim of the project is to develop a globally innovative hybrid testing system for the detection of antibodies specific for COVID-19 and other cold viruses.

The successful implementation of R&D activities will lead to the development of a new multifunctional ELISA test that will be easily applicable in all hospital laboratories as they already have the necessary equipment. High-sensitivity tests will also be developed to check the response to several viral antigens at once, which will improve the accuracy of the test.

Start of project activities implementation: 15/01/2021

End of project activities implementation - 31/12/2021

UAB Imunodiagnostika investments in the production of diagnostic tests

UAB Imunodiagnostika implements the project UAB Imunodiagnostika's investments in the production of diagnostic tests,  No. 03.3.1-LVPA-T-859-0026, financed by the European Regional Development Fund (project budget - € 769,298.14, funding allocated - € 730,833.23).  €).

The aim of the project is to develop an appropriate infrastructure for the production of diagnostic tests for the detection of COVID-19 specific IgG and IgM class antibodies.

The project will aim to create an infrastructure for the cultivation and isolation of test protein producers from yeast and tissue cultures. In addition to the standard equipment required for solution production and storage of blanks, a semi-automatic solution packaging line is planned to be installed in the solution production unit in order to maximize the automation of the solution packaging process.

Development of a customized allergy diagnostic tool based on the principle of artificial intelligence

UAB Imunodiagnostika implements the project “Development of an Individual Allergy Diagnostic Tool Operating on the Principle of Artificial Intelligence”, No. 01.2.1-LVPA-K-856-01-0225, financed from the European Regional Development Fund (project budget - € 1,447,516.87, funding allocated - € 1,039,255.41). The aim of the project is to create a globally innovative allergy diagnostic tool (an individualized allergy diagnostic tool based on artificial intelligence). With the help of the developed diagnostic tool, it will be possible to make allergy diagnoses based on the results of blood tests faster, easier and without missing important information (eliminating the human factor as much as possible).

Innovative tools for allergy diagnosis and treatment

UAB Imunodiagnostika implements the project “Innovative tools for allergy diagnostics and treatment” (project No. J05-LVPA-K-03-0086) according to the 2014-2020. Measure No. of the European Union Funds Investment Operational Program Priority 1 “Promotion of Research, Experimental Development and Innovation” J05-LVPA-K “Intelligence. Joint Science-Business Projects ”, which is funded by the European Regional Development Fund. The aim of the project is to develop a globally innovative product of biotechnological commercial value - recombinant proteins with diagnostic properties of reagents. During the project, the company will add new equipment to its existing infrastructure, which will be used for research and development of a new product. The recombinant proteins / allergens developed during the project will meet the rapidly changing market realities:

• The developed technology will allow economical and standardized production of large quantities of recombinant allergens, which will be superior to those produced by other methods.

• The development of highly immunoreactive recombinant allergens would significantly improve the sensitivity and specificity of diagnostic tests;

• Recombinant allergens / proteins produced in the plant system would replace native allergen proteins in immunotherapy